Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Although chemotherapy remains among the best treatment options for most cancers, adjuvant therapies such as dendritic cell (DC)-based immunotherapy have been added to treatment protocols to destroy residual tumour cells. Combination treatment with low-dose temozolomide (TMZ) chemotherapy followed by vaccination with TAT-survivin-pulsed DCs enhanced T-cell responses specific for survivin and improved survival rate, as compared with DC alone or TMZ alone. Moreover, antigen-specific immunity appears to be mediated by CD8(+) T cells, as determined by in vitro T-cell subset depletion. These studies demonstrated that a combination of low-dose TMZ chemotherapy and TAT-based DC immunotherapy may be a novel strategy for safe and effective treatment of malignant gliomas.
Kim
Chang-Hyun
CH
Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea.
Woo
Sun-Je
SJ
Park
Jung-Sun
JS
Kim
Hye-Sung
HS
Park
Mi-Young
MY
Park
Sung-Dong
SD
Hong
Yong-Kil
YK
Kim
Tai-Gyu
TG
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D051017:Apoptosis Regulatory Proteins / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D049109:Cell Proliferation; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000637:transplantation*; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D007111:Immunity, Cellular; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D008869:Microtubule-Associated Proteins / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012097:Repressor Proteins; D013154:Spleen / Q000276:immunology; D016019:Survival Analysis; D000077022:Survivin; D000077204:Temozolomide; D014161:Transduction, Genetic; D016896:Treatment Outcome; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000276:immunology
D018906:Antineoplastic Agents, Alkylating; D051017:Apoptosis Regulatory Proteins; C117749:Birc5 protein, mouse; D019496:Cancer Vaccines; C512124:HIV-TAT-survivin (T34A) protein; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; D000077022:Survivin; D054322:tat Gene Products, Human Immunodeficiency Virus; D003606:Dacarbazine; D000077204:Temozolomide